Published in Vaccine Weekly, March 10th, 1997
Immunization with vaccines containing HBV surface antigen (HBsAg), prepared from plasma or by genetic engineering, has been effective in preventing the establishment of chronic HBV infections, but approximately 14 percent of vaccinees remain only...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.